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Introduction
Diabetes mellitus and its associated complications is a 
major challenge for both the private and state health 
sector in South Africa. The number of people with 
diabetes is increasing because of population growth, 
ageing, urbanisation and the increasing prevalence of 
obesity and physical inactivity.
Subclinical hypothyroidism is defined as an elevated 
serum TSH level, with serum thyroid hormone concen-
trations within the normal range.1 According to the 
literature, subclinical hypothyroidism affects 3-8% of 
the general Western population.2 Symptoms may 
be present or absent. Most patients have TSH levels 
< 10 IU/ml and are asymptomatic. The cause of 
subclinical hypothyroidism is usually that of autoimmune 
thyroid disease. 
Patients with diabetes have a higher prevalence of 
thyroid disorders than people in the normal population 
(10.8% vs. 6.6% as quoted in one USA study).3 An 
outpatient study of patients with diabetes in Scotland, 
who were screened for thyroid disease, reported the 
prevalence to be 13.4%. The most common abnormality 
was subclinical hypothyroidism.4
Patients with one organ-specific, autoimmune disease 
are at risk of developing other autoimmune disorders. 
Thyroid disorders are also more common in females, 
and it was found that up to 40% of female patients with 
type 1 diabetes had thyroid disease.5 Eight per cent of 
these patients had subclinical hypothyroidism.5
A number of reports have also indicated a higher-than-
normal prevalence of thyroid disorders in patients with 
type 2 diabetes. Subclinical hypothyroidism was the 
most common disorder.3 The prevalence of subclinical 
hypothyroidism in patients with type 2 diabetes varies 
in the literature. Some studies stated that subclinical 
hypothyroidism was found in 10-17% of patients 
suffering from diabetes mellitus,4,6-8 while others gave 
a more conservative prevalence of 5-7%.9 The latter 
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Abstract
Objective: The purpose of this study was to determine the prevalence of subclinical hypothyroidism among patients 
with diabetes mellitus at the Kalafong Diabetes Clinic in Pretoria.
Design: Cross-sectional study.
Setting and subjects:  Five hundred and sixty-five patients with diabetes mellitus (type 1, type 2 or unknown), who 
were following-up at the Kalafong Hospital Diabetes Clinic. 
Outcome measures: The thyroid stimulating hormone (TSH) levels of patients were evaluated. Patients with TSH levels 
> 5.66 IU/ml (upper reference limit of the Kalafong National Health Laboratory Services laboratory) subsequently 
underwent repeat thyroid function evaluation, including T4 level, to determine the prevalence of subclinical 
hypothyroidism. 
Results: A total of 563 patients met the inclusion criteria for this study and underwent TSH evaluation. The prevalence 
of subclinical hypothyroidism was found to be 0.9% in the study population, and 1.6% in a subgroup of patients with 
type 2 diabetes mellitus.
Conclusion: The prevalence of subclinical hypothyroidism in this South African population of patients with diabetes 
was significantly lower than that stated in the literature. This holds true for both the general population and 
populations of patients with diabetes mellitus. To our knowledge, there is no data available for the prevalence of 
subclinical hypothyroidism in the general population in South Africa for comparison with the study group. 
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is comparable with the prevalence quoted in the 
general population. 
Data that pertain to the prevalence of subclinical 
hypothyroidism in the South African general population, 
as well as to South African patients with diabetes 
mellitus, is lacking.
In a cross-sectional study in Taiwan that reviewed 
556 patients with type 2 diabetes and subclinical 
hypothyroidism, there was an associated higher 
frequency of nephropathy, after adjustment for age, 
sex and haemoglobin A1c (HbA1c).
10 The prevalence 
of nephropathy in these patients was 48%. Their data 
suggest that the higher incidence of cardiovascular 
events in subclinical hypothyroidism with type 2 
diabetes might be mediated by nephropathy. 
The endothelial dysfunction that is associated with 
subclinical hypothyroidism is manifest by thickening of 
the capillary basement membrane and small vessel 
dysfunction, leading to retinopathy.11,12 In a study that 
compared the prevalence of diabetic retinopathy 
in patients with type 2 diabetes and subclinical 
hypothyroidism to their euthyroid counterparts, it was 
evident that severe retinopathy was significantly more 
common in the former group.13 These results were 
after adjustment for age, sex, duration of diabetes, 
HbA1c, body mass index, hypertension and low-density 
lipoprotein (LDL) cholesterol. Patients with type 2 
diabetes and subclinical hypothyroidism were found 
to be at an increased risk of sight-threatening diabetic 
retinopathy.
Subclinical hypothyroidism can elevate serum LDL 
cholesterol and worsen pre-existing dyslipidaemia, 
further increasing the risk of atherosclerosis in patients 
with type 2 diabetes.3
Insulin resistance and its associated disorders is more 
common in patients with subclinical hypothyroidism.14 
The other effects of subclinical hypothyroidism include 
reductions in hepatic glucose output, gluconeogenesis 
and peripheral glucose utilisation (because of impaired 
translocation of the glucose transporter receptor). The 
net effect of these processes is a predisposition to 
hypoglycaemia. Frequent hypoglycaemic episodes 
were documented in children and adolescents with 
diabetes and subclinical hypothyroidism. Treatment 
led to an improvement in hypoglycaemic symptoms in 
this patient group.15
In the general population, there is a clear association 
with an increase in coronary heart disease and 
subclinical hypothyroidism, especially in persons 
< 65 years of age. Re-analysis of the Whickham Survey 
Cohort (which evaluated vascular events over 20 years 
in community-dwelling subjects, stratified by thyroid 
function and thyroid auto-antibody status) confirmed 
that the incidence of ischaemic heart disease 
was significantly higher in patients with subclinical 
hypothyroidism, as was ischaemic heart disease-
related mortality.16
Data from the Rotterdam Cohort indicate that 
subclinical hypothyroidism is a strong, independent risk 
factor for cardiovascular disease, particularly in elderly 
women.17 Subclinical hypothyroidism was associated 
with a greater prevalence of aortic atherosclerosis 
[odds ratio (OR)1.7] and myocardial infarction (OR 2.3).
The above refers to patients with subclinical 
hypothyroidism in the general population. It is suggested 
that subclinical hypothyroidism is a co-mediator for 
cardiovascular risk, in association with nephropathy, in 
patients with diabetes. However, it has not been shown 
to be an independent risk factor for cardiovascular 
disease in patients with diabetes mellitus.10 
There is a significant correlation between HbA1c and TSH 
levels. There is an improvement of metabolic control 
after treatment of subclinical hypothyroidism.18
Of patients with subclinical hypothyroidism, 2-5% per 
year will progress to overt hypothyroidism, while 5% 
will spontaneously revert to normal thyroid functions.14 
Since overt hypothyroidism is an established indication 
for replacement therapy with T4, patients who are 
identified as suffering from subclinical hypothyroidism 
should be monitored intermittently for progression.
Method
Setting
This cross-sectional study was conducted on adult 
patients with diabetes mellitus and receiving routine 
care at the Kalafong Hospital Diabetes Clinic. All 
patients underwent TSH testing as part of annual 
investigations carried out at the clinic. 
Patient selection
All patients on the clinic’s database who were seen 
during 2010 were included in the study, provided they 
had signed informed consent for their information to be 
used, and that they did not meet any of the following 
exclusion criteria:
• Age < 18 years.
• History of thyroid disease or thyroid hormone 
replacement therapy.
• Hospitalisation or severe illness at the time of 
evaluation or preceding month (which could be 
associated with nonthyroidal illness that relates to 
abnormalities in thyroid function tests).
Measurements
TSH, creatinine, LDL cholesterol, HbA1c levels and 
microalbuminuria levels were determined by the 
National Health Laboratory Service at Kalafong 
Hospital.
In this study:
• An elevated TSH level was defined as ≥ 5.66 IU/ml.
• A LDL cholesterol level > 2.5 mmol/l was considered 
to be elevated. 
Original Research: The prevalence of subclinical hypothyroidism among patients with diabetes mellitus
108 2013 Volume 18 No 2JEMDSA
• Microalbuminuria was defined as a urinary albumin 
to creatinine ratio of 3.3-30 mg/mmol in a spot urine 
sample.
• Macroalbuminuria was defined as a urinary albumin 
to creatinine ratio of > 30 mg/mmol.
• Nephropathy was defined as a urine albumin 
to creatinine ratio of > 3.3 mg/mmol or serum 
creatinine > 176.8 µmol/l.
• Glycaemic control was documented by HbA1c.
• Retinopathy was classified into three categories: no 
retinopathy, preproliferative diabetic retinopathy 
and proliferative diabetic retinopathy. Fundoscopy 
was performed in the diabetic clinic as part of the 
standard care by the physicians who were treating 
the patients. Any retinopathy defined as equal to 
or greater than preproliferative retinopathy was 
considered to be relevant.
Follow-up
Any patient with an abnormally elevated TSH level 
underwent further evaluation with T4 levels to exclude 
the presence of primary hypothyroidism. 
Statistical analysis
Microsoft® Access® 2003 was used to capture data. 
Statistical analysis was carried out with IBM SPSS® 
(version 19, 2010). 
Statistical analysis consisted of descriptive statistics. 
Normally distributed data ere compared with the 
t-test and skewed data with the Mann-Whitney U test. 
Categorical data were compared with the chi-square 
test and the Fisher exact test.
Proportions were compared using Medcalc® (version 
11.3.1.0, 2010).
Results
Five hundred and ninety patients were reviewed on 
the diabetes clinic database, of which 563 patients 
met inclusion criteria for this study and underwent TSH 
testing. Of the patients who were included in the study, 
two were found to have primary hypothyroidism and 
they were excluded from further analysis. 
The study population consisted of 563 patients, of 
which 347 (62%) were female and 216 (38%) were 
male. Five hundred and twenty-one (93%) of the study 
population were of black ethnicity, 19 (3%) patients 
were white, 18 (3%) were Indian, while the remaining 
5 (1%) represented patients of coloured ethnicity. 
The average age of the studied population was 56.9 
± 14.8 years, with the mean duration of diabetes being 
11.9 ± 8.3 years. 
The study population included 182 (32%) patients with 
type 1 diabetes, 361 (65%) patients with type 2 diabetes 
and 14 (3%) patients in whom the type of diabetes was 
unknown. Patient characteristics are shown in Table I.
Table I: Characteristics of diabetic patients evaluated for 
subclinical hypothyroidism (n = 563)









Type 1 182 (32%)
Type 2 361 (65%)
Unknown 16 (3%)
Duration of diabetes (years, SD) 14.7 ± 8.3
Co-morbid hypertension 439 (78%)
Current use of statin 289 (51.3%)
TSH level (IU/ml), median (IQR) 1.59 (1.05-2.35)
HbA1c%, median (IQR) 7.7 (6.5-9.7)
Total cholesterol (mmol/l), mean, SD 4.5 ± 1.02
LDL (mmol/l), mean, SD 2.53 ± 0.89
HDL (mmol/l), mean, SD 1.19 ± 0.34
TG (mmol/l), median (IQR) 1.5 (1-2.2)
Serum creatinine (µmol/l) median (IQR) 83.0 (70-104.8)
Urine albumin/creatinine ratio, median (IQR) 1.0 (0.4-4.13)
HbA1c: haemoglobin A1c, HDL: high-density lipoprotein, IQR = interquartile 
range; LDL: low-density lipoprotein, SD = standard deviation, TG: triglycerides, 
TSH: thyroid-stimulating hormone
The prevalence of subclinical hypothyroidism in the 
studied population of patients with diabetes mellitus 
was 0.9% [confidence interval (CI): 0.296-2.077] for 
the group as a whole, and 1.4% (CI: 0.45-3.259) in the 
subgroup of patients with type 2 diabetes. 
Five of the 563 screened patients were found to have 
subclinical hypothyroidism. All five patients were of 
African descent and suffered from type 2 diabetes. 
Three of the patients were female and two were male. 
Four of these patients suffered from concomitant 
hypertension and dyslipidaemia.
Subgroups within the study population were compared 
in terms of gender, race and type of diabetes. 
Compared variables included TSH levels, cholesterol 
profiles (total cholesterol, LDL, high-density lipoprotein 
and triglycerides), microalbuminuria and HbA1C. The only 
statistically significant differences between male and 
female groups were found in HDL cholesterol, as well 
as LDL cholesterol. Both were increased in females 
more so than in males, with a mean difference in LDL 
cholesterol of 0.417 mmol/l (p-value < 0.001) and HDL 
cholesterol of 0.212 mmol/l (p-value < 0.001).
Nonparametric testing was carried out to compare 
the group of patients with subclinical hypothyroidism 
(defined by the TSH cut-off of 5.66 IU/ml) with the 
remaining patients in the study group. There was 
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a statistically significant difference in the serum 
creatinine values, which were higher in the group 
with subclinical hypothyroidism by a mean of 
4.3 µmol/l (p-value = 0.017).
An attempt was made to build a logistic regression 
model in order to evaluate the difference in 
nephropathy, retinopathy and lipid profile between 
those patients with normal thyroid function and those 
with subclinical hypothyroidism. Unfortunately, the 
latter group was too small to obtain any covariates 
which were statistically significant.
Discussion
The purpose of this study was to determine the 
prevalence of subclinical hypothyroidism among 
patients with diabetes mellitus in a South African 
context. We found the prevalence to be 0.9% in the 
study population and 1.6% in the subgroup of patients 
with type 2 diabetes. 
To the best of our knowledge, this is the first report on 
the prevalence of subclinical hypothyroidism among 
patients with diabetes mellitus in a South African 
context. Data is also lacking on the prevalence of 
subclinical hypothyroidism in the population as a 
whole.
The prevalence of subclinical hypothyroidism that 
was found in this study was much lower than that 
published in the international literature. This statistically 
significant difference was found when comparing the 
prevalence of subclinical hypothyroidism in our study 
population with the prevalence that was quoted in both 
the general population and the diabetic population. 
The difference holds true for our cut-off reference TSH 
of 5.66 IU/ml, as well as the 4.2 IU/ml that was used in 
many of the international studies. Table II compares the 
prevalence of subclinical hypothyroidism in our study 
population with that that was published.4,6-7
Many of the published studies used laboratory tests 
with an upper limit of normal for TSH of 4.2 IU/ml. A 
subanalysis of the data was carried out using this 
reference range, and it was found that if this cut-
off was used, 4.2% (CI: 2.459-5.848) of the study 
population would be classified as having subclinical 
hypothyroidism, while 4.1% (CI: 2.281-6.738) of patients 
with type 2 diabetes would be classified as such. 
If the TSH cut-off of 4.2 IU/ml is used, 22 (3.9%) 
patients were identified as suffering from subclinical 
hypothyroidism. Of these, 7 (1.2%) had type 1 diabetes 
and 15(2.6%) type 2. Four patients in this group were 
Indian, one was white and the remaining 17 were 
of black ethnicity. The prevalence of concomitant 
dyslipidaemia in this group was 54.5%. 
Most of the studies that were performed on 
the prevalence and significance of subclinical 
hypothyroidism were carried out in a context of 
European and Eastern population groups. Very few, 
if any, black patients were included in these studies. 
The largest proportion of our population comprises 
patients of black ethnicity. The results of our study 
raise the question of whether reference ranges, which 
were determined in a Western population, can be 
extrapolated to a demographically different South 
African population. As with many of the laboratory 
tests that are used in South Africa, the reference range 
for the thyroid function tests employed by the National 
Health Laboratory Services was set based on the 
normal data of a Western population, rather than on 
normal values for the local population. 
A study that was carried out in Israel by Ishay 
et al8 determined the prevalence of subclinical 
hypothyroidism in women with type 2 diabetes, 
with that of women in the general population. They 
found the difference between the two groups to be 
statistically insignificant (9% in patients with diabetes, 
compared to 8% in the general population). The 
prevalence of subclinical hypothyroidism in this study 
group of patients with diabetes was lower than stated 
in other studies, and the author concluded that routine 
screening of thyroid function in patients with type 2 
diabetes is unwarranted. However, even this more 
modest estimation of the prevalence of subclinical 
hypothyroidism in patients with diabetes was much 
higher than that found in our population.
Table II: Prevalence of subclinical hypothyroidism in this study 
compared to that that was published
Published 
%




General population prevalence of subclinical hypothyroidism 
(3-8%)
3 5.66 0.9, 563 0.26 to 2.08 0.0034
4.2 3.9, 563 2.46 to 5.85 0.2160
8 5.66 0.9, 563 0.26 to 2.08 < 0.0001
4.2 3.9, 563 2.46 to 5.84 0.0003
Diabetes population prevalence of subclinical hypothyroidism 
(10-17%)
10 5.66 0.9, 563 0.26 to 2.08 < 0.0001
4.2 3.9 2.46 to 5.85 < 0.0001
13 5.66 0.9, 563 0.26 to 2.08 < 0.0001
4.2 3.9 2.46 to 5.85 < 0.0001
17 5.66 0.9, 563 0.26 to 2.08 < 0.0001
4.2 3.9 2.46 to 5.85 < 0.0001
Diabetes type 2 population prevalence of subclinical 
hypothyroidism (10-17%)
10 5.66 1.4, 361 0.45 to 3.26 < 0.0001
4.2 4.1 2.28  to 6.74 < 0.0001
13 5.66 1.4, 361 0.45 to 3.26 < 0.0001
4.2 4.1 2.28 to 6.74 < 0.0001
17 5.66 1.4, 361 0.45 to 3.26 < 0.0001
4.2 4.1 2.28 to 6.74 < 0.0001
CI: confidence interval, TSH: thyroid-stimulating hormone
Original Research: The prevalence of subclinical hypothyroidism among patients with diabetes mellitus
110 2013 Volume 18 No 2JEMDSA
The results of our study lend itself to the same 
conclusion as that of Ishay et al. It may not be cost-
effective to routinely screen patients with diabetes 
mellitus with thyroid function tests, unless it is clinically 
indicated. However, baseline TSH levels can predict 
the future development of hypothyroidism in patients 
with diabetes mellitus. Patients with a baseline TSH 
of greater than 2.2 IU/ml have an increased risk of 
developing hypothyroidism.1 Targeted screening of this 
subgroup of patients may be more cost-effective than 
universal annual screening. Patients with positive thyroid 
autoantibodies, and those at risk of polyglandular 
autoimmune endocrinopathy, also warrant routine 
annual screening of thyroid function tests.14
The upper limit of the reference range for TSH has been 
a contentious issue in the literature. A large Dutch 
population-based survey defined a much narrower 
range of TSH levels of between 0.3 and 2.5 IU/ml.17 It is 
argued that more than 95% of normal individuals have 
TSH levels below 2.5 IU/ml. Furthermore, the population-
based studies in which the reference ranges for 
TSH were determined previously, featured patients 
undergoing an initial phase of autoimmune thyroid 
disease. This could have potentially skewed the upper 
reference limit.18 
Using an upper reference limit of 2.5 IU/ml for TSH to 
define subclinical hypothyroidism, as proposed in the 
literature, would have increased the prevalence of 
subclinical hypothyroidism in our population to 21% in 
the group as a whole, and to 23% in patients with type 2 
diabetes. However, none of the studies that described 
outcomes in patients with subclinical hypothyroidism 
used such a low threshold to diagnose the condition. 
Consensus has not been reached about the level of TSH 
which defines the upper limit of normal. The definition 
of subclinical hypothyroidism remains related to the 
assay-specific upper limit of the TSH reference range. 
Therefore, the upper limit of normal for TSH of 5.66 IU/l, 
used in our laboratory, was used as the cut-off value.
A shortcoming of this study was the lack of data in 
the South African general population with which 
to compare our findings in a diabetic population. 
The upper limit of normal for TSH at our institution’s 
laboratory has been determined for the specific assay 
used. However, the reference range was derived from 
the normal values in the Western population where the 
test was manufactured, leaving much to be desired in 
terms of determining what is “normal” in our population.
This study has highlighted the need for further studies to 
determine the normal reference range of TSH in a South 
African context, which contains a greater proportion of 
black patients than that in Western populations. 
Once the aforementioned data is available, the 
definition of subclinical hypothyroidism can be 
customised to our population, and its prevalence more 
accurately determined.
Screening for thyroid dysfunction among patients 
with diabetes mellitus remains a cost versus benefit 
dilemma. Furthermore, the literature supports treatment 
of subclinical hypothyroidism only in those with a TSH 
level >10 IU/l, or those with thyroid antibodies.14
One strategy, which is supported in the literature, is to 
screen all patients with diabetes once with a TSH level, 
and repeat annual screening only in those with TSH 
levels that are greater than 2.2 IU/ml, or those which 
comprise a high risk for subsequent hypothyroidism 
(patients with the polyglandular autoimmune syndrome 
and those with positive thyroid antibodies).
Conclusion
The prevalence of subclinical hypothyroidism among 
a South African population of patients with diabetes 
mellitus at the Kalafong Diabetes Clinic was 0.9%. The 
prevalence among the subgroup of patients with 
type 2 diabetes was 1.6%. Both of these values are 
statistically significantly lower than the prevalence of 
subclinical hypothyroidism quoted in the literature for 
patients with diabetes and for the general population. 
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